Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from POLARIS.

Gabrielle B. Rocque,Joanne L. Blum,Aldemar Montero,Meghan Sri Karuturi,Kenneth Manning,Lloyd A. Shabazz,Christopher Gallagher,Lara Zuberi,Joseph C. Cappelleri,Marc Drucker,Yao Wang,Debu Tripathy

Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from POLARIS.

2021

Gabrielle B. Rocque
Joanne L. Blum
Aldemar Montero
Meghan Sri Karuturi
Kenneth Manning
Lloyd A. Shabazz
Christopher Gallagher
Lara Zuberi
Joseph C. Cappelleri
Marc Drucker
Yao Wang
Debu Tripathy

1071Background: Racial disparities in breast cancer incidence, mortality, and care are well documented. PAL plus endocrine therapy is indicated for patients (pts) with HR+/HER2− ABC. Findings from ...

Keywords:

endocrine therapy
Medicine
Internal medicine
Palbociclib
Oncology
Hormone receptor
Cancer
Quality of life
Subgroup analysis
Incidence (epidemiology)
Breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations